Asthma +me (CE-marked, Class 1 Medical Device): RCT for digital alternative care pathway to unblock paediatric asthma outpatient clinics.

Lead Participant: ASEPTIKA LIMITED

Abstract

Asthma is the most common chronic medical condition among children and young people in the UK and an NHS priority (NHS England). 932,000 children in England receive treatment for asthma. It is the most frequent reason for emergency admission and the UK has the third highest risk of death from childhood asthma in OECD nations (Asthma UK).

The current care management programme is based on primary care visits and referral to specialist clinics as required. Asthma UK's recent report ""Slipping through the net"" identifies the need for referral to specialist paediatric centres for children and young people with difficult or severe asthma as they are at greatest risk without expert care.

Our CE-Marked Asthma+me care solution for children and young people with stable but difficult or severe asthma and will be used to support them and their families keep well at home.

It combines:

* self-care technology
* education
* training
* support
* data sharing with primary, secondary and tertiary care, to support existing out-patient care

Asthma+me is a solution that helps NHS paediatric centres meet NICE guidelines for self-care and addresses the needs identified by Asthma UK in their ""Slipping through the net"" report (July 2018).

https://www.asthma.org.uk/globalassets/get-involved/external-affairs-campaigns/publications/severe-asthma-report/auk-severe-asthma-gh-final.pdf

Lead Participant

Project Cost

Grant Offer

ASEPTIKA LIMITED £232,500 £ 116,250
 

Participant

INNOVATE UK

Publications

10 25 50